



NDA 20-287/S-008

Pharmacia & Upjohn  
Attention: James H. Chambers  
7000 Portage Road  
Kalamazoo, Michigan 49001-0199

MAR 30 1999

Dear Mr. Chambers:

Please refer to your supplemental new drug application dated April 16, 1997, received April 17, 1997, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Fragmin® (dalteparin sodium injection).

We acknowledge receipt of your submissions dated May 9, June 11 and 12, August 13, November 21, 1997, and February 25, March 19, September 8, and November 6, 1998. Your submission of November 6, 1998 constituted a complete response to our April 15, 1998 action letter.

This supplemental new drug application provides for the use of Fragmin® for prophylaxis of deep vein thrombosis (DVT), which may lead to pulmonary embolism, in patients undergoing hip replacement surgery.

We have completed the review of this supplemental application, as amended, and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the enclosed labeling text. Accordingly, the supplemental application is approved effective on the date of this letter.

The final printed labeling (FPL) must be identical to the enclosed labeling (text for the package insert).

Please submit 20 copies of the FPL as soon as it is available, in no case more than 30 days after it is printed. Please individually mount ten of the copies on heavy-weight paper or similar material. For administrative purposes, this submission should be designated "FPL for approved supplement NDA 20-287/S-008." Approval of this submission by FDA is not required before the labeling is used.

In addition, please submit three copies of the introductory promotional materials that you propose to use for this product. All proposed materials should be submitted in draft or mock-up form, not final print. Please submit one copy to this Division and two copies of both the promotional materials and the package insert directly to:

Division of Drug Marketing, Advertising, and Communications, HFD-40  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, Maryland 20857

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Practitioner" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2  
FDA  
5600 Fishers Lane  
Rockville, MD 20857

Please submit one market package of the drug product when it is available.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

If you have any questions, contact Karen Oliver, Regulatory Health Project Manager, at (301) 827-7310.

Sincerely,



Lilia Talarico, M.D.  
Director  
Division of Gastrointestinal and Coagulation Drug  
Products  
Office of Drug Evaluation III  
Center for Drug Evaluation and Research